Home
Biosimilars and Biobetters
29 September - 30 September 2014
Biosimilars and Biobetters

Impending patent expirations on blockbuster biologics and a volatile financial environment is causing payers to seek wider adoption of biosimilars in order to manage growing healthcare costs. As a result, the biosimilars manufacturing market is set to expand over the next decade and beyond as the drive to find cost-effective alternatives to biologics leads to the growing. In fact analysts predict that between 2013-2018, the global biosimilars market will grow at 27.58 %.

Returning for its fitfth year and following on from the major success of previous events, SAE Media Group are proud to present the 5th annual Biosimilars & Biobetters Conference, 29th-30th September, 2014, London. With an in-depth focus on the current and future landscape of the biosimilars market, this meeting will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.

Join us and be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding biosimilar commercial and manufacturing developments.

Key topics include:

• Biosimilars, biobetters - the patients perspective
• The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry
• What is on the horizon? ... Reviewing the opportunities and challenges for the biopharmaceutical industry
• Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars
 
• And much more!

Previous testimonial:
“A thoroughly interesting and very informative conference with excellent chairs and presenters. More of the same please - Abbott

Dear Visitor, HEREyou can download:

- List of attendees – 2014
- List of past attendees (2011-2013)

FEATURED SPEAKERS

Michel  Mikhail

Michel Mikhail

Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi
Peter Wittner

Peter Wittner

Senior Consultant, Interpharm Consultancy
Richard Dicicco

Richard Dicicco

Chairman, Harvest Moon Pharmaceuticals
Steinar Madsen

Steinar Madsen

Medical Director, Norwegian Medicines Agency

Alan Sheppard

Global Head Generics, Thought Leadership, IMS Health
Alan Sheppard

Albin (Jim) Nelson

Partner, Schwegman, Lundberg, Woessner IP, P.A.
Albin (Jim) Nelson

Alok Sharma

Principal Scientist & Head Analytical Development , Lupin Laboratories Ltd
Alok Sharma

Carsten Brockmeyer

CEO, Formycon AG
Carsten Brockmeyer

Catherine Akers

Regulatory Affairs Manager, Amgen Inc
Catherine Akers

Dominic Adair

Partner, Bristows
Dominic Adair

Erik A. Stene

Senior Advisor/MPhil Econ, Department for pharmacoeconomics/reimbursement/value assessment, Norwegian Medicines Agency
Erik A. Stene

Ineke Braat

CEO, PanGenerika
Ineke Braat

Liz Fuller

Partner, Bird & Bird
Liz Fuller

Michael Tovey

INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan
Michael Tovey

Michel Mikhail

Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi
Michel  Mikhail

Peter Wittner

Senior Consultant, Interpharm Consultancy
Peter Wittner

Rakesh Dixit

Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune (AstraZeneca Biologics)
Rakesh Dixit

Ranjith Gopinathan

Program Manager - Life Sciences, Healthcare Practice Europe, Frost & Sullivan
Ranjith  Gopinathan

Richard Dicicco

Chairman, Harvest Moon Pharmaceuticals
Richard Dicicco

Robin Chadwick

Partner, Schwegman, Lundberg, Woessner IP
Robin Chadwick

Samuel Woodley

U.S. Senior Patent Attorney, Biosimlars Business, Boehringer Ingelheim Pharma GmbH & Co. KG
Samuel Woodley

Sarah Faircliffe

Legal Director , Bird & Bird
Sarah Faircliffe

Steinar Madsen

Medical Director, Norwegian Medicines Agency
Steinar Madsen

Uwe Gudat

Head of Safety Biosimilars, Merck Switzerland Limited
Uwe Gudat

Victoria Fine

Managing Director , Psoriansense
Victoria Fine

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Michel  Mikhail

Michel Mikhail, Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi

clock

9:10

Regulatory overview EU and US

An update on the EU and US regulatory requirements for biosimilars

clock

9:50

EU and US regulatory pathway

A refreshment of the current regulatory pathways for biosimilars in the EU and USA.

clock

10:30

Morning Coffee

clock

11:00

Biosimilars regulatory overview in India

A description of the regulatory requirement in India and the published biosimilars guideline

clock

11:40

Biosimilars Wrap-up, Questions and Answers

Allowing the workshop participants to interact and exchange experiences

clock

12:20

Closing remarks

clock

12:30

End of workshop

clock

13:30

Registration & Coffee

clock

14:00

Opening remarks

Ineke Braat

Ineke Braat, CEO, PanGenerika

clock

14:10

Session 1: Questions you should ask within your organisation before starting to produce biosimilars

clock

14:50

Session 2: Biosimilars what is the ROI for working with them?

clock

15:30

Coffee break

clock

16:00

Session 3 : Why and more important; how do you introduce biosimilars

clock

16:40

Session 4 : Is there a yellow brick road?

clock

17:20

Closing Remarks

clock

17:30

End of workshop

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

clock

9:10

What is on the horizon? ... Reviewing the opportunities and challenges for the biopharmaceutical industry

Alan Sheppard

Alan Sheppard, Global Head Generics, Thought Leadership, IMS Health

• Reviewing the sustainability of the biosimilars market, will it be saturated in the future?
• The big question…who will be most successful, those who are:
o the fastest to market
o generates the most similar biosimilar
• Evaluating the barriers to market entry and uptake for biosimilars
• Where are we heading and what needs to happen

clock

9:50

The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

• Understanding how this will shape the competitive, dynamic and commercially lucrative biosimilars market segment
• Reviewing why big pharma companies are considering entering with market with monoclonal antibody biosimilars
• Will their experience in marketing, manufacturing skills and industry knowledge give them a competitive advantage over those already in the market
• What are their weaknesses?

clock

10:30

Morning Coffee

clock

10:50

A clinical perspective on biosimilars: development and beyond

Uwe Gudat

Uwe Gudat, Head of Safety Biosimilars, Merck Switzerland Limited

• The challenge - creating strategies to overcome the obstacles we face
• The means - utilizing the tools at our disposal
• The scenarios - a collection of possible outcomes
 

clock

11:30

Biosimilars/ Biobetters in the USA

• US PTO regulations extending the impact of the Myriad decision
• Strategy and hurdles for patenting your biosimilar in the US
• Update on evolving FDA regulations for biosimilars: why are there no approvals in the US?

Albin (Jim) Nelson

Albin (Jim) Nelson, Partner, Schwegman, Lundberg, Woessner IP, P.A.

Robin Chadwick

Robin Chadwick, Partner, Schwegman, Lundberg, Woessner IP

clock

12:10

Networking Lunch

clock

13:10

Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars

• Taking an in-depth look at the discussion regarding the WHOs initiative for a unique identifier for biologics – what will this mean?
• The use of identical INNs for biosimilars could lead to inadvertent switching at the pharmacy - true or false?
• What is the view at home and abroad?
• USA - GphA and originator citizen petitions to the FDA

Peter Wittner

Peter Wittner, Senior Consultant, Interpharm Consultancy

clock

13:50

You can’t injunct me – I’m a biosimilar!

Dominic Adair

Dominic Adair, Partner, Bristows

• Review of the principles governing interim injunctions in patent litigation
• Application of those principles to pharma cases
• Why biosimilar cases may not necessarily be a good fit – will the injunctions stick?
 

clock

14:30

European update - the latest in regulatory thinking

• Understanding current regulatory legislation and guidelines for biosimilars in Europe, reviewing the regulatory pathways in other jurisdictions •
• What are the regulatory requirements for non-clinical and clinical studies in developing biosimilars  
• Other aspects of the regulatory framework to consider when preparing a marketing authorisation application

 

 

 

Sarah Faircliffe

Sarah Faircliffe, Legal Director , Bird & Bird

Liz Fuller

Liz Fuller, Partner, Bird & Bird

clock

15:10

Afternoon Tea

clock

15:30

The case for biosimilars–a payer’s perspective

Erik A. Stene

Erik A. Stene, Senior Advisor/MPhil Econ, Department for pharmacoeconomics/reimbursement/value assessment, Norwegian Medicines Agency

•         Why are payers interested in utilizing biosimilars?
•         Switching or not switching in pharmacies?
•         Switching or not switching for economical reasons after treatment initiation/during treatment?
•         What will happen in Norway onwards?

clock

16:10

Same, similar, equivalent, this is a serious game! Proving that a biosimilar is ‘similar’ to the originator is not trivial pursuit!

Michael Tovey

Michael Tovey, INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan

• Defining biosimilarity
• How similar is the biosimilar to the innovator…measuring how much work this entails  at the early stage
• Evaluating what metrics and analytical similarity assessments should be employed when designing a biosimilar development program
• Determining type and volume of clinical data required for establishing biosimilarity
• Establishing validated standardized assays that allow direct comparisons of the relative potency and immunogenicity of the biosimilar and the innovator product
• Considering the limitations of conventional biological assays that may be inadequate to detect differences resulting from a change in the manufacturing process
• Conducting a non-clinical or a clinical study

clock

16:50

Pre-Launch supply readiness for biosimilars

Samuel Woodley

Samuel Woodley, U.S. Senior Patent Attorney, Biosimlars Business, Boehringer Ingelheim Pharma GmbH & Co. KG

• Understanding the “safe harbor” provisions against patent infringement in the United States
• The Board exemption to patent infringement, across the European Union and in individual countries
• Maximizing benefit of the exemptions to minimize risks of infringement before launch

clock

17:30

Chairman’s Closing Remarks and Close of Day One

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

clock

9:10

Biosimilars - hurdles to patients' access

Michel  Mikhail

Michel Mikhail, Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi

• Development of biosimilars: A case study
• Patent protection
• INN issue
• Switching: interchangeability and substitution

clock

9:50

What do they really think...Reviewing customer perceptions of biosimilars in Europe

Ineke Braat

Ineke Braat, CEO, PanGenerika

• Discussing what do doctors think of biosimilars and how willing are they to prescribe them
• Monitoring how patients react when their doctor prescribes a biosimilar?
• Are payors pushing for more utilization of biosimilars in Europe
 

clock

10:30

Morning Coffee

clock

10:50

Innovations in creating best in class biosuperior biologics: meeting the challenges of biosimilars

Rakesh Dixit

Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune (AstraZeneca Biologics)

clock

11:30

Pharmacovigilance considerations for biologics and biosimilars

Catherine Akers

Catherine Akers, Regulatory Affairs Manager, Amgen Inc

• Unique characteristics for biologics which influence their safety profile
• Importance for accurate traceability to allow effective pharmacovigilance
• How biologics have been recognised in the new EU pharmacovigilance legislation and what implementation looks like across Europe.


 

clock

12:10

Networking Lunch

clock

13:10

Tracking the introduction of biosimilar infliximab in Norway

Steinar Madsen

Steinar Madsen, Medical Director, Norwegian Medicines Agency

• What are the attitudes of physicians?
• Switching study – what is the status?  
• Monitoring prices and sales
 

clock

13:50

Designing and executing comparability studies…an important ‘key’ in the development of products

Alok Sharma

Alok Sharma, Principal Scientist & Head Analytical Development , Lupin Laboratories Ltd

clock

14:30

Afternoon Tea

clock

14:50

Biosimilars, biobetters - the patients perspective

Victoria Fine

Victoria Fine, Managing Director , Psoriansense

• A patients understanding of biologics, biobetters & biosimilars
• What biosimilars & biobetters actually mean to patients
• The true impact of biosimilars and biobetters
 

clock

15:30

A new dawn… biosimilar monoclonal antibodies (mAbs), a new milestone for the biosimilar market!

Carsten Brockmeyer

Carsten Brockmeyer, CEO, Formycon AG

• Reviewing how approval of the first biosimilar monoclonal antibody therapy will impact the industry, what are the implications for 2014 and beyond
• Evaluating if this will spearhead the start of a new era of mAbs in the pharma industry
• Discussing how to get regulatory approval for your mAb
• Will this bring greater commercial rewards
• Will generic companies continue to dominate, or can Big Pharma gain control with its huge marketing muscle?

 

clock

16:10

Market dynamics in biosimilars

Ranjith  Gopinathan

Ranjith Gopinathan, Program Manager - Life Sciences, Healthcare Practice Europe, Frost & Sullivan

clock

16:50

Chairman’s Closing Remarks and Close of Day Two

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals


Global Head Generics, Thought Leadership
IMS Health
Partner
Schwegman, Lundberg, Woessner IP, P.A.
Principal Scientist & Head Analytical Development
Lupin Laboratories Ltd
CEO
Formycon AG
Regulatory Affairs Manager
Amgen Inc
Partner
Bristows
Senior Advisor/MPhil Econ, Department for pharmacoeconomics/reimbursement/value assessment
Norwegian Medicines Agency
CEO
PanGenerika
Partner
Bird & Bird
INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology
Ecole Normale Supérieure de Cachan
Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations
Fresenius Kabi
Senior Consultant
Interpharm Consultancy
Vice President, R&D, Global Head, Biologics Safety Assessment
MedImmune (AstraZeneca Biologics)
Program Manager - Life Sciences, Healthcare Practice Europe
Frost & Sullivan
Chairman
Harvest Moon Pharmaceuticals
Partner
Schwegman, Lundberg, Woessner IP
U.S. Senior Patent Attorney, Biosimlars Business
Boehringer Ingelheim Pharma GmbH & Co. KG
Legal Director
Bird & Bird
Medical Director
Norwegian Medicines Agency
Head of Safety Biosimilars
Merck Switzerland Limited
Managing Director
Psoriansense

Sponsors and Exhibitors

Official Media Partner

Supporters

Workshops

Biosimilars – A Regulatory Update

Biosimilars – A Regulatory Update

Holiday Inn Regents Park
1 October 2014
London, United Kingdom

Biosimilars – ‘The Holy Grail?’

Biosimilars – ‘The Holy Grail?’

Holiday Inn Regents Park
1 October 2014
London, United Kingdom

Biosimilars and Biobetter - 2014 Attendees

Download

Biosimilars and Biobetters - Speakers Interviews 2014

Download

Sponsorship Manual

Download

PAST CONFERENCE ATTENDEES (2011-2013) BY COMPANY AND COUNTRY

Download

Sponsors and Exhibitors


Europa Bioproducts Ltd

Sponsors and Exhibitors
http://www.europa-bioproducts.com

Europa Bioproducts is the exclusive distributors for ProZyme Inc., who manufactures a very comprehensive range of reagents used for glycan profiling and characterization of therapeutic monoclonal antibodies and proteins. The GlykoPrep rapid glycan preparation technology allows companies with no previous experience to perform glycan analysis in house. After collaboration with Agilent Technologies, GlykoPrep has been automated on the Agilent Bravo liquid handling platform. We now have customers performing high throughput glycan profiling for clone selection and culture media optimization with this platform. Europa/ProZyme is now offering analytical support services to their European customers. We offer screening services for 100’s of samples using UPLC or CE. We can perform orthogonal methods such as UPLC and CE. We can perform in depth characterisation of N-Glycans using UPLC/MS, exoglycosidases and also domain specific analysis of antibodies.


Schwegman, Lundberg & Woessner

Sponsors and Exhibitors
http://www.slwip.com/

Schwegman Lundberg & Woessner is a nationally recognized boutique IP firm focused on strategic patent procurement with over 140 patent practitioners that have robust backgrounds across a wide spectrum of technology areas. Schwegman's clients include multinational corporations, middle-market businesses, universities, as well as start-ups and individual inventors.

Media Partners


BiosimilarNews

Official Media Partner
http://www.Biosimilarnews.com

Biosimilarnews.com is a weblog to share the knowledge about biosimilars. We wanted to build up a detailed source for professionals and also for the public. Our only aim is to share our knowledge and also keep in touch with the professionals who are working in this specific area. Biosimilar News - We keep you up to date.

Media Partners


Pharmaceutical International

Supporters
http://www.pharmaceutical-int.com

Pharmaceutical International is a total resource for buyers such as chemists, pharmacists, industrial pharmaceutical manufacturers, legislative bodies, hospitals, research laboratories and other people within the industry who have annual buying power of billions of pounds estimated to be in the region of £400 billion per year. Pharmaceutical International is a total resource enabling the user to find the latest exhibitions, events, suppliers, products and services servicing the entire industry today. Whether you are searching for a simple pill or a turnkey laboratory solution you should be able to find the answer on this comprehensive web platform.


Pharma Marketing News

Supporters
http://www.news.pharma-mkting.com/

Pharma Marketing News is an independent monthly electronic newsletter focused on issues of importance to pharmaceutical marketing executives. It is a service of the Pharma Marketing Network -- The First Forum for Pharmaceutical Marketing Experts -- which brings together pharmaceutical marketing professionals from manufacturers, communications companies, and marketing service providers for wide ranging discussions and education on a multitude of current topics. Pharma Marketing Network & Pharma Marketing News provide executive-level content coupled with permission-based e-marketing opportunities.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


PharmCast

Supporters
http://www.PharmCast.com

www.PharmCast.com is the world leading website designed specifically for pharmaceutical, clinical and biotechnology professionals. www.PharmCast.com brings up-to-date information on pharmaceutical patents, FDA, news, jobs and Buyer's Guide to our visitors. It was created and is maintained by pharmaceutical and biotechnology professionals. Visit www.PharmCast.com and discover for yourself why it is so popular among professionals.


Thomson Reuters

Supporters
http://thomsonreuters.com/products_services/science/

Thomson Reuters is the leading source of intelligent information for professionals around the world. We provide essential information to keep you in touch with the rapidly-changing pharmaceutical and chemical markets, expert services to help you make informed, early decisions, and intuitive technology to manage and support your discovery and development activities. Our products give you the intelligence, tools and expertise to help you optimize your IP portfolio, monitor industry developments, identify licensing and partnering opportunities, deliver successful regulatory submissions, and support your scientific messaging, marketing, product positioning, and awareness campaigns.


Farmavita

Supporters
https://farmavitar.com

FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


Frost & Sullivan

Supporters
http://www.frost.com

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Register: Gain access to visionary innovation


Lab Bulletin

Supporters
http://www.labbulletin.com

Lab Bulletin is a free online resource for scientists and laboratory professionals where you can catch up on the latest news for laboratory products and services. You will find an extensive directory of laboratory suppliers and manufacturers enabling you to contact companies quickly and easily to request further information. Lab Bulletin also publishes four free monthly E-Newsletters keeping you up-to-date with all of the latest laboratory products and industry news directly to your inbox. We have dedicated E-Newsletters for Chromatography and Spectroscopy, Microscopy and Image Analysis, weekly Industry News updates and our monthly Lab Bulletin E-Newsletter sent out to over 29,000 readers worldwide. To request your free copy click here


Antibodies Online

Supporters
http://www.antibodies-online.com

antibodies-online.com facilitates researchers to find the appropriate antibodies for their respective research project. As an independent and multi-vendor marketplace for research antibodies and thanks to the cooperation with more than 130 different manufacturers, a large selection of Antibodies (over 700,000), ELISA Kits (over 130,000), Secondary Antibodies (17,000), Proteins (130,000), Peptides and Isotype Controls is available. By supporting the Independent Validation Initiative and the Resource Identification Initiative, antibodies-online.com also addresses the important topics of transparent product quality and scientific reproducibility. In addition scientists receive news and detailed information about the individual antibodies from databases such as the PubMed and others.


Technology Networks

Supporters
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


World Pharma Today

Supporters
http://www.worldpharmatoday.com



Bioportfolio Limited

Supporters
http://www.bioportfolio.com

BioPortfolio.com is a leading news, information and knowledge resource covering the global life science industries impacted by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to source core information on specific bio-related topics, to collate relevant data associated with each topic and to point the user to relevant knowledge resources


Biotechnology Europe

Supporters
http://www.biotechnology-europe.com

BIOTECHNOLOGY-EUROPE.com is provided by BIOTECHNOLOGY WORLD, facilitates the exchange of information by promoting research within biotech sector. These include all participants in the sector such as government bodies, researchers, consumers, biotechnology companies, journalists and venture capital companies, biotech nationals organizations. Links and collaborations with other industrial networks add up to the BIOTECHNOLOGY-EUROPE`s own extensive database.


GBI

Supporters
http://www.gbihealth.com/

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


Biotechgate

Supporters
http://www.biotechgate.com/gate/v3/companies.php

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 38,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.


Pharmacircle

Supporters
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


LabRoots

Supporters
http://www.labroots.com/

LabRoots is a free, social networking site that enables scientists, engineers, and other technical professionals to connect, collaborate with, and learn from each other. LabRoots fosters world-wide scientific communication and incorporates the newest social networking technologies. LabRoots allows scientists to connect with each other as they describe their research interests on a myriad of unique features and tools, discovering meaningful collaborations across geographic boundaries and fields of expertise.


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


Select Science

Supporters
http://www.selectscience.net/

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


Mednous

Supporters
http://www.MedNous.com

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


Drug Target Review

Supporters
http://www.drugtargetreview.com

Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


Cutting Edge

Supporters
http://www.cuttingedgeinfo.com

Cutting Edge Information provides customized research and benchmarking reports to pharmaceutical, biotechnology and other life science companies. We provide off-the-shelf and customized research for key areas including medical affairs, clinical development, market access, regulatory affairs, marketing management, sales and HCP fair market value.

Holiday Inn Regents Park

Carburton Street
London W1W 5EE
United Kingdom

Holiday Inn Regents Park

Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download

Title


Description

Download

Title


Description


Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

Group Booking

Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SAE Media Group

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smgconferences.com Email: events@saemediagroup.com
Registered in England - SMi Group Ltd trading as SAE Media Group




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SAE Media Group.
Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

Fill in your details to download the brochure

By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.